NCT02831582View on ClinicalTrials.gov

Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

December 11, 2021

Study Completion Date

December 11, 2021

Conditions

ArthralgiaBreast Neoplasms

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fatty Acid

Given PO.

OTHER

Placebo

Given PO.

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

91010

City of Hope, Duarte

All Listed Sponsors

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT02831582 - Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer | Biotech Hunter | Biotech Hunter